First Patient Dosed in Phase 1b Trial Testing Cirmtuzumab Add-on in HER2-negative Breast Cancer Patients

First Patient Dosed in Phase 1b Trial Testing Cirmtuzumab Add-on in HER2-negative Breast Cancer Patients
A pilot Phase 1 trial evaluating Oncternal Therapeutic’s investigational therapy cirmtuzumab as an add-on to standard chemotherapy for patients with advanced, HER2-negative breast cancer who cannot receive surgery has started dosing participants. Cirmtuzumab is a human monoclonal antibody designed to bind to the receptor-tyrosine-kinase like orphan receptor 1 (ROR1), a protein located at the surface of breast cancer cells. Tumor cells that express ROR1 have a higher potential to divide and contribute to tumor growth and spread. By binding to ROR1, cirmtuzumab blocks signals that promote cancer cell survival. "Expression of ROR1 on primary breast cancers has been shown to be associated with a higher risk of relapse over time, and is correlated with markers of EMT (epithelial-mesenchymal transition). Treatment of breast cancer cells in the laboratory with cirmtuzumab, which binds with high affinity to cell-surface ROR1, inhibits tumor growth and metastasis," James Breitmeyer, MD, PhD, Oncternal's president and CEO, said in a press release. The Phase 1b study (NCT02776917), ongoing at the University of California, San Diego and currently recruiting participants, is an open-label, non-randomized, fixed-dose study. Its primary goal is to determine the safety and tolerability of the combination therapy. Patients will receive cirmtuzumab, administered into th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.